GC Biopharma Overview

  • Year Founded
  • 1967

Year Founded

  • Status
  • Public

  • Employees
  • 150

Employees

  • Stock Symbol
  • 005250

Stock Symbol

  • Investments
  • 36

  • Share Price
  • $7.18
  • (As of Friday Closing)

GC Biopharma General Information

Description

GC Corp focuses on healthcare-related activities, including the diagnosis, prevention, treatment, and management of diseases.

Contact Information

Website
www.gcbiopharma.com
Formerly Known As
GC Pharma, Sudo Microorganism Medical Supplies Company, Green Cross Company, Suh-Doo Microbial Pharmaceutical
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 107 Ihyeon-ro 30beon-gil
  • Giheung
  • Yongin, Gyeonggi 16924
  • South Korea
+82
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Stock Exchange
KRX
Vertical(s)
Manufacturing
Corporate Office
  • 107 Ihyeon-ro 30beon-gil
  • Giheung
  • Yongin, Gyeonggi 16924
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GC Biopharma Stock Performance

As of 13-Nov-2026, GC Biopharma’s stock price is $7.18. Its current market cap is $326M with 45.2M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$7.18 $7.27 $5.98 - $12.06 $326M 45.2M 77.5K -$1.85

GC Biopharma Financials Summary

As of 30-Jun-2026, GC Biopharma has a trailing 12-month revenue of $1.71B.

In Thousands,
USD 		TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,842,007 2,133,028 2,047,163 2,181,115
Revenue 1,713,958 1,722,586 1,615,945 1,574,008
EBITDA 29,722 84,453 150,857 46,141
Net Income (84,162) (48,845) 17,608 (41,406)
Total Assets 2,707,534 2,825,796 2,491,951 2,900,416
Total Debt 1,096,019 1,037,004 764,527 993,394
Public Fundamental Data provided by Morningstar, Inc. disclaimer

GC Biopharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore GC Biopharma‘s full profile, request access.

Request a free trial

GC Biopharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
GC Corp focuses on healthcare-related activities, including the diagnosis, prevention, treatment, and management of dise
Pharmaceuticals
Yongin, South Korea
150 As of 2025

Basel, Switzerland
 

Rahway, NJ
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

GC Biopharma Competitors (3)

One of GC Biopharma’s 3 competitors is Roche, a Corporation company based in Basel, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Roche Corporation Basel, Switzerland
Merck & Co. Corporation Rahway, NJ
Novartis Corporation Basel, Switzerland
You’re viewing 3 of 3 competitors. Get the full list »

GC Biopharma Patents

  • 2,665

    Total Documents Applications and Grants

  • Total Patents Families

  • 1,001

    Granted

  • 89

    Pending

  • Expiring in next 12 mo

GC Biopharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4836990-A1 Multispecific antibody for lysosomal degradation Pending 06-Jan-2025
EP-4836991-A1 Multispecific antibody for lysosomal degradation Pending 06-Jan-2025
WO-2026147080-A1 Amine-based cyclolipid compound for nucleic acid delivery and lipid nanoparticles comprising same Pending 03-Jan-2025
WO-2026095655-A1 A novel nucleic acid molecule with improved expression efficiency and sustainability and uses thereof Pending 30-Oct-2024
WO-2026071610-A1 Composition comprising selective organ targeting lipids Pending 24-Sep-2024
To view GC Biopharma’s complete patent history, request access »

GC Biopharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GC Biopharma Investments & Acquisitions (36)

GC Biopharma’s most recent deal was a PIPE with Artiva Biotherapeutics for . The deal was made on 08-May-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Artiva Biotherapeutics 08-May-2026 PIPE Drug Discovery
GC & Phenica Healthcare Center 05-Dec-2025 Joint Venture Clinics/Outpatient Services
Curevo Vaccine 06-Mar-2025 Later Stage VC Drug Discovery
Inibio 12-Feb-2025 Secondary Transaction - Private Biotechnology
ABO Plasma 18-Dec-2024 Merger/Acquisition Biotechnology
You’re viewing 5 of 36 investments and acquisitions. Get the full list »

Ready to get started?

Request a free trial

GC Biopharma ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

28.94 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,585

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view GC Biopharma’s complete esg history, request access »

GC Biopharma Exits (16)

GC Biopharma’s most recent exit was on 08-May-2026 from Artiva Biotherapeutics. The exit was categorized as with 12 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Artiva Biotherapeutics 08-May-2026 Completed
  • 12 buyers
Curevo Vaccine 06-Mar-2025 Completed
  • 8 buyers
Kanaph Therapeutics 02-Jan-2024 Completed
  • 8 buyers
Curevo Vaccine 16-Nov-2022 Completed
  • 5 buyers
GOM2 Project 18-Jul-2022 Early Stage VC Completed
You’re viewing 5 of 16 exits. Get the full list »

GC Biopharma Affiliates

Subsidiaries (5)

Name Industry Location Year Founded
ABO Plasma Irvine, CA 2020
Made Scientific Princeton, NJ 2019
Genes Lab Seongnam-si, South Korea 2008
GC MediAI Seoul, South Korea 1992
Sang-A Pharmaceutical Seoul, South Korea

GC Biopharma FAQs

  • When was GC Biopharma founded?

    GC Biopharma was founded in 1967.

  • Where is GC Biopharma headquartered?

    GC Biopharma is headquartered in Yongin, South Korea.

  • What is the size of GC Biopharma?

    GC Biopharma has 150 total employees.

  • What industry is GC Biopharma in?

    GC Biopharma’s primary industry is Pharmaceuticals.

  • Is GC Biopharma a private or public company?

    GC Biopharma is a Public company.

  • What is GC Biopharma’s stock symbol?

    The ticker symbol for GC Biopharma is 005250.

  • What is the current stock price of GC Biopharma?

    As of 13-Nov-2026 the stock price of GC Biopharma is $7.18.

  • What is the current market cap of GC Biopharma?

    The current market capitalization of GC Biopharma is $326M.

  • What is GC Biopharma’s current revenue?

    The trailing twelve month revenue for GC Biopharma is $1.71B.

  • Who are GC Biopharma’s competitors?

    Roche, Merck & Co., and Novartis are competitors of GC Biopharma.

  • What is GC Biopharma’s annual earnings per share (EPS)?

    GC Biopharma’s EPS for 12 months was -$1.85.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process